Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
5 clinical trials · Sponsor
◉ Watch Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
| Record | Firm | Date |
|---|---|---|
| A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants (NCT06977880) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2025-02-19 |
| A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (NCT06226883) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2024-07-18 |
| A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (NCT05611671) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2022-11-21 |
| A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC (NCT05291689) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2022-04-13 |
| Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (NCT04580745) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2020-09-23 |
Track Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) automatically
Every clearance here is in the API, with alerts when new ones post.